Clinical trials: Advanced Lung Non-Small Cell Carcinoma
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell…
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT01282333
- Testing
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.
- Trial name
- NCT02580708
- Testing
- Rociletinib, Trametinib
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Clovis Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
The main aim of this study is to evaluate the safety and tolerability of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR) mutation(s)…
- Trial name
- NCT02044380
- Testing
- Afatinib
- Where
- 5 sites in Canada
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and in studies using animals; however, it is not known…
- Trial name
- NCT00907179
- Testing
- LBH 589, Pemetrexed
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pittsburgh
Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)
Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study
This is a pilot study to test the hypothesis that biofeedback-mediated stress management (BFSM) training can be used to reduce distress and enhance quality of life in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT01685346
- Testing
- biofeedback-mediated stress management (BFSM)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients
The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer.
- Trial name
- PULMO-01 (NCT06879717)
- Testing
- roginolisib, Dostarlimab, Docetaxel
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 45 people
- Sponsor
- iOnctura
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and…
- Trial name
- REZILIENT2 (NCT05967689)
- Testing
- TAS6417, CYP Cocktail, Transporter Cocktail
- Where
- 80 sites in United States, Australia and 10 more
- Volunteers
- 220 people
- Sponsor
- Taiho Oncology, Inc.
Non Small Cell Lung Cancer, Cardiotoxicity
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
- Trial name
- NCT07761910
- Testing
- PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Indiana University
NSCLC
Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer
Study Arms: Patients receive autologous dendritic cells pulsed with antigen peptides ID on days 15, 29, 43,57,71,99,127and 155, and nivolumab IV over 60 minutes on days 15, 29, 43,57,71,85 99 and 113.
- Trial name
- NCT04199559
- Testing
- Autologous dendritic cells pulsed with antigen
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Non-Small-Cell Lung Carcinoma
Molecular Imaging With Erlotinib and Bevacizumab
The patients will be treated with erlotinib and bevacizumab for a six-week period. Imaging procedures will be performed at baseline, after one week of therapy and after the six weeks of treatment.
- Trial name
- MIMEB (NCT01047059)
- Testing
- Erlotinib, Bevacizumab, Fluoro-D-glucose, Fluoro-L-thymidine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Cologne
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
- Trial name
- ATLANTIC (NCT02087423)
- Testing
- MEDI4736
- Where
- 139 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Radiation Therapy to Relieve Symptoms in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study will test the safety of Quad Shot radiation therapy using 2 different treatment schedules to find out what effects, if any, this treatment has on people with advanced NSCLC who are receiving systemic therapy for their…
- Trial name
- NCT04384146
- Testing
- Cyclical Hypofractionated Palliative Radiation (Quad Shot), EORTC QLQ-C30 questionnaire
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Malignancies, Non-small-cell Lung Cancer
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.
- Trial name
- NCT04181788
- Testing
- PF-06801591
- Where
- 49 sites in China, Japan and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.
- Trial name
- NCT06015568
- Testing
- MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD
- Where
- 3 sites in China
- Volunteers
- 172 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer
Phase II trial to study the effectiveness of bortezomib in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00040768
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Lung Cancer
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy.
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II
- Trial name
- NCT03999710
- Testing
- Radiation Therapy, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00101920
- Testing
- ABX-EGF
- Volunteers
- 50 people
- Sponsor
- Amgen
Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous…
- Trial name
- CheckMate 169 (NCT02475382)
- Testing
- Nivolumab
- Where
- 50 sites in Brazil, Canada
- Sponsor
- Bristol-Myers Squibb
NSCLC Stage IV
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
This study is an open-label, multicenter, phase II single arm trial to evaluate the efficacy and safety of SBRT in combination with sintilimab and GM-CSF for the treatment of patients with advanced NSCLC.
- Trial name
- NCT04106180
- Testing
- GM-CSF, Sintilimab, SBRT
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer
Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer
This is a pilot study looking at using stereotactic radiosurgery and full dose chemotherapy to treat stage II and III lung cancer that is not amendable to surgical resection.
- Trial name
- NCT02568033
- Testing
- Pemetrexed, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The Cooper Health System